Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional

Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant

ClinicalTrials.gov ID: NCT02490202

Public ClinicalTrials.gov record NCT02490202. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Placebo-controlled, Prospective, Double-blind, Multicenter Phase 2/3 Study of the Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant

Study identification

NCT ID
NCT02490202
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Prolong Pharmaceuticals
Industry
Enrollment
60 participants

Conditions and interventions

Interventions

  • SANGUINATE Drug
  • Normal Saline Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2015
Primary completion
Jul 31, 2016
Completion
Sep 30, 2016
Last update posted
Oct 26, 2016

2015 – 2016

United States locations

U.S. sites
20
U.S. states
14
U.S. cities
18
Facility City State ZIP Site status
Mayo Clinic Phoenix Phoenix Arizona 85054
University of California, Los Angeles Los Angeles California 90024
California Institute of Renal Research San Diego California 92123
California Pacific Medical Center San Francisco California 94115
University of California San Francisco San Francisco California 94143
Medstar Georgetown University Hosiptal Washington D.C. District of Columbia 20007
Tampa General Hospital Tampa Florida 33606
Augusta University Augusta Georgia 30912
Northwestern University Chicago Illinois 60611
UIC University of Illinois at Chicago Chicago Illinois 60612
Ochsner Medical Center New Orleans Louisiana 70121
Henry Ford Hospital Detroit Michigan 48212
Saint Barnabas Medical Center Livingston New Jersey 07039
The Cleveland Clinic Cleveland Ohio 44195
University of Toledo Toledo Ohio 43537
Central Pennsylvania Transplant Foundation Harrisburg Pennsylvania 17104
University of Pittsburg Medical Center Pittsburgh Pennsylvania 15213
Medical University of South Carolina Charleston South Carolina 29425
Houston Methodist Hospital Houston Texas 77030
University of Wisconsin Madison Wisconsin 53706

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02490202, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 26, 2016 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02490202 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →